TMCnet News
Forty Seven, Inc. to Present Updated Data from Ongoing Phase 1b/2 Clinical Trial of 5F9 in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma at 24th Congress of the European Hematology AssociationMENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that updated data from its ongoing Phase 1b/2 clinical trial evaluating 5F9 in combination with rituximab for the treatment of relapsed/refractory non-Hodgkin’s lymphoma (r/r NHL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), will be presented in an oral presentation at the 24th Congress of the European Hematology Association (EHA) in Amsterdam, Netherlands, June 13-16, 2019. In an additional oral presentation, Forty Seven will present initial data from its Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). These data in AML and MDS will have been previously presented in a poster session on Monday, June 3, 2019 at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Details on the presentations are as follows: Presentation Title: The first-in-class anti-CD47 antibody HU5F9-G4 with rituximab induces durable responses in relapsed/refractory DLBCL and indolent lymphoma: interim phase 1b/2 results Location: Hall 5 Presentation Title: The first-in-class anti-CD47 antibody HU5F9-G4 is active and well tolerated alone or in combination with azacitidine in AML and MDS patients: initial phase 1b results The accepted abstracts are now available online on the EHA website: https://ehaweb.org/congress/eha24/key-information/. About Forty Seven Inc.: For journalist enquiries please contact Sarah Plumridge at [email protected] or phone (312) 506-5219. For investor enquiries please contact Hannah Deresiewicz at Stern Investor Relations Inc. at [email protected] or phone (212) 362-1200. |